FR11C0036I1 - SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL - Google Patents

SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL

Info

Publication number: FR11C0036I1
Authority: FR; France
Prior art keywords: pharmaceutical compositions; compositions containing; receptor agonist; sugar alcohol; solid pharmaceutical
Prior art date: 2003-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR11C0036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Mitsubishi Tanabe Pharma Corp

Original Assignee

Novartis AG

Tanabe Seiyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2011-09-08

Publication date

2011-10-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-08 Application filed by Novartis AG, Tanabe Seiyaku Co Ltd filed Critical Novartis AG

2011-10-14 Publication of FR11C0036I1 publication Critical patent/FR11C0036I1/en

2023-12-29 Application granted granted Critical

2023-12-29 Publication of FR11C0036I2 publication Critical patent/FR11C0036I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Surgery (AREA)
Virology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

FR11C0036C 2003-04-08 2011-09-08 SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL Active FR11C0036I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en)	2003-04-08	2004-04-06	Organic compounds

Publications (2)

Publication Number	Publication Date
FR11C0036I1 true FR11C0036I1 (en)	2011-10-14
FR11C0036I2 FR11C0036I2 (en)	2023-12-29

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (en)	2003-04-08	2004-04-06	SOLID PHARMACEUTICAL COMPOSITION COMPRISING S1P RECEPTOR AGONIST AND SUGAR ALCOHOL
FR11C0036C Active FR11C0036I2 (en)	2003-04-08	2011-09-08	SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (en)	2003-04-08	2004-04-06	SOLID PHARMACEUTICAL COMPOSITION COMPRISING S1P RECEPTOR AGONIST AND SUGAR ALCOHOL

Country Status (41)

Country	Link
US (11)	US20060275357A1 (en)
EP (5)	EP2008650A3 (en)
JP (3)	JP5495467B2 (en)
KR (3)	KR20050121712A (en)
CN (2)	CN101797241B (en)
AR (3)	AR043987A1 (en)
AT (3)	ATE414508T1 (en)
AU (1)	AU2004228929B2 (en)
BE (2)	BE1015972A5 (en)
BR (1)	BRPI0409250B8 (en)
CA (2)	CA2521325C (en)
CL (2)	CL2004000745A1 (en)
CY (3)	CY1110260T1 (en)
DE (4)	DE122011100047I1 (en)
DK (2)	DK2316431T3 (en)
EC (1)	ECSP056090A (en)
ES (3)	ES2556947T3 (en)
FR (2)	FR2854073B1 (en)
GB (1)	GB2400318B (en)
GR (1)	GR1005052B (en)
HR (3)	HRP20100601B1 (en)
HU (2)	HUE028247T2 (en)
IL (3)	IL170888A (en)
IS (2)	IS2682B (en)
IT (1)	ITMI20040682A1 (en)
LU (1)	LU91867I2 (en)
MA (1)	MA27729A1 (en)
MX (1)	MXPA05010860A (en)
MY (1)	MY141249A (en)
NO (4)	NO329332B1 (en)
NZ (3)	NZ542622A (en)
PE (5)	PE20150676A1 (en)
PL (2)	PL1613288T3 (en)
PT (1)	PT1613288E (en)
RU (5)	RU2358716C2 (en)
SG (1)	SG175449A1 (en)
SI (2)	SI2316431T1 (en)
TN (1)	TNSN05256A1 (en)
TW (1)	TWI332847B (en)
WO (1)	WO2004089341A1 (en)
ZA (1)	ZA200507394B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1993115B (en) *	2004-07-30	2011-12-28	诺瓦提斯公司	Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (en) *	2005-07-07	2010-10-13	马启明	Oral preparation and its preparing method
MX2008003170A (en) *	2005-09-09	2008-03-18	Novartis Ag	Treatment of autoimmune diseases.
KR101434522B1 (en)	2005-11-09	2014-08-26	오닉스 세라퓨틱스, 인크.	Compounds for enzyme inhibition
TWI389683B (en) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RU2450016C2 (en)	2006-06-19	2012-05-10	Протеоликс, Инк.	Peptide epoxy ketones for proteasome inhibition
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
KR102044064B1 (en) *	2006-09-26	2019-11-12	노파르티스 아게	Pharmaceutical compositions comprising an s1p modulator
EP1923058A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) *	2006-09-26	2008-04-02	Novartis AG	Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) *	2007-02-14	2008-10-16	Emory University	Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ597109A (en)	2007-03-29	2013-01-25	Daiichi Sankyo Co Ltd	Tablet composition having favorable dissolution property useful as an anticoagulant
SI2207791T2 (en)	2007-10-04	2019-09-30	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JOP20080436B1 (en) *	2007-10-12	2023-03-28	Novartis Ag	Compositions comprising sphingosine I phosphate (S1P) receptor modulators
JP5534645B2 (en) *	2008-01-11	2014-07-02	日医工株式会社	Oral dosage formulation containing sarpogrelate hydrochloride with excellent stability in an unwrapped state
WO2009099174A1 (en)	2008-02-07	2009-08-13	Kyorin Pharmaceutical Co., Ltd.	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
AR070842A1 (en)	2008-03-17	2010-05-05	Actelion Pharmaceuticals Ltd	DOSAGE REGIME FOR A S1P1 SELECTIVE RECEIVER AGONIST
EP2303250A1 (en)	2008-06-20	2011-04-06	Novartis AG	Paediatric compositions for treating1 multiple sclerosis
KR101647855B1 (en) *	2008-06-20	2016-08-11	메르크 파텐트 게엠베하	Directly injection moldable and rapidly disintegrating tablet matrix
EP2334202B1 (en) *	2008-09-04	2012-02-01	Cargill, Incorporated	Tabletting of ervthritol
EP2796134B1 (en)	2008-10-21	2016-12-07	Onyx Therapeutics, Inc.	Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
AU2013100531B4 (en) *	2008-11-11	2013-11-28	Novartis Ag	Crystalline forms of fingolimod HCL
EP2358660A2 (en)	2008-11-11	2011-08-24	Novartis AG	Salts of fingolimod
KR20130109254A (en) *	2008-11-11	2013-10-07	노파르티스 아게	Crystalline forms of fingolimod hcl
JP5305421B2 (en)	2008-12-17	2013-10-02	第一三共株式会社	Method for producing diamine derivative
JPWO2010082531A1 (en)	2009-01-13	2012-07-05	第一三共株式会社	Activated blood coagulation factor inhibitor
ES2542236T3 (en)	2009-03-10	2015-08-03	Daiichi Sankyo Company, Limited	Production process of a diamine derivative
JP5652879B2 (en)	2009-03-13	2015-01-14	第一三共株式会社	Method for producing optically active diamine derivative
AR075899A1 (en)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	PROTEASA INHIBITING CRYSTALLINE EPOXYCETON TRIPEPTIDES
CA2765522A1 (en) *	2009-06-18	2010-12-23	Daiichi Sankyo Company, Limited	Solid pharmaceutical composition of edoxaban having improved solubility
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2498793B1 (en)	2009-11-13	2019-07-10	Onyx Therapeutics, Inc.	Oprozomib for use in metastasis suppression
AU2011223795B2 (en)	2010-03-01	2015-11-05	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
EP2548879B1 (en)	2010-03-19	2015-12-09	Daiichi Sankyo Company, Limited	Crystal of diamine derivative and method of producing same
EP2548556B1 (en)	2010-03-19	2016-08-10	Daiichi Sankyo Company, Limited	Method for improving dissolvability of anticoagulant
WO2011131368A2 (en) *	2010-04-22	2011-10-27	Ratiopharm Gmbh	A method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (en)	2010-07-02	2017-12-01	다이이찌 산쿄 가부시키가이샤	Process for preparation of optically active diamine derivative salt
US9266816B2 (en)	2010-11-25	2016-02-23	Shilpa Medicare Limited	Fingolimod polymorphs and their processes
UA114283C2 (en)	2011-01-07	2017-05-25	Новартіс Аг	COMPOSITIONS OF IMMUNOSUPRESSANTS
NO2665471T3 (en)	2011-01-19	2018-05-26
JO3177B1 (en)	2011-04-01	2018-03-08	Novartis Ag	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
US9186333B2 (en) *	2011-08-01	2015-11-17	Teva Pharmaceutical Industries Ltd.	Process for preparing pharmaceutical compositions of fingolimod
CA2844604C (en)	2011-08-10	2017-07-18	Daiichi Sankyo Company, Limited	Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en)	2011-12-22	2013-06-27	Synthon Bv	Pharmaceutical composition comprising fingolimod
RU2482842C1 (en) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Pharmaceutical composition of s1p receptor agonist for treatment of demyelinating diseases (versions) and method of its obtaining
RU2506949C1 (en) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases
US20140105921A1 (en)	2012-07-09	2014-04-17	Onyx Therapeutics, Inc.	Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (en) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Pharmaceutical composition exhibiting improved flowability, drug preparation, method for preparing and using
EP2943189B1 (en) *	2013-01-08	2021-03-10	Pathologica LLC	Mitoguazone for treatment of progressive multiple sclerosis
WO2014141298A2 (en) *	2013-03-11	2014-09-18	Astron Research Limited	Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) *	2013-04-26	2019-06-05	Kyoto University	Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (en) *	2013-05-13	2020-07-01	Synthon Bv	Pharmaceutical composition comprising fingolimod
EP3027174B1 (en)	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Pharmaceutical compositions of fingolimod
RU2530626C1 (en) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Pharmaceutical composition of s1p receptor agonist for treating demyeliniating diseases
WO2016026461A1 (en) *	2014-08-22	2016-02-25	Sunshine Lake Pharma Co., Ltd.	Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
AU2016209466A1 (en) *	2015-01-20	2017-08-10	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (en) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Method of producing capsules of fingolimod hydrochloride
US9690975B2 (en)	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Stable formulations of fingolimod
GR1009654B (en)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Pharmaceutical composition comprising an immunomodulatory agent and method for the preparation thereof
DE102018217334A1 (en) *	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents
JP7503420B2 (en) *	2020-05-18	2024-06-20	東和薬品株式会社	Pharmaceutical composition containing fingolimod, and its manufacturing method and stabilization method
WO2022015348A1 (en)	2020-07-16	2022-01-20	Harbins Ruhr Bioscience, Inc.	Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
WO2022162088A2 (en) *	2021-01-28	2022-08-04	Priothera Sas	Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (en) *	1976-07-12	1978-01-16	Akzo Nv	PROCESS FOR PREPARING NEW PEPTIDES AND PEPTIDE DERIVATIVES AND THEIR USE
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en) *	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (en) *	1990-11-29	1998-12-24	田辺製薬株式会社	Long-term stable oral pharmaceutical preparation
US5604229A (en)	1992-10-21	1997-02-18	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en)	1994-08-22	2002-01-09	Welfide Corporation	Benzene compound and medicinal use thereof
SK282225B6 (en)	1995-12-28	2001-12-03	Welfide Corporation	Use of 2-amino-2[2-(octylphenyl)ethyl]-propane-1,3-diol or its pharmaceutically acceptable additive salt with acid for production of pharmaceutical preparation
JP2002241272A (en) *	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	Pharmaceutical formulation composition
JPH11209277A (en) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	Pharmaceutical composition
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
SI0990440T1 (en) *	1997-02-27	2009-04-30	Novartis Ag	PHARMACEUTICAL COMPOSITION COMPRISING 2-AMINO-2-?á2-(4-OCTYLPHENYL)ETHYL?åPROPANE-1,3-DIOL, A LECITHIN AND A SACCHARIDE
SI1319651T1 (en) *	1997-04-04	2005-10-31	Mitsubishi Pharma Corporation	2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (en) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	Novel immunosuppressants, methods of use and methods of identification thereof
JP3545595B2 (en)	1998-04-01	2004-07-21	花王株式会社	Production method of glycosphingolipid
JP4627356B2 (en) *	1999-06-30	2011-02-09	昭松森	Drugs for preventing or treating viral myocarditis
WO2001003739A1 (en) *	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate
SK152003A3 (en)	2000-07-13	2004-07-07	Sankyo Co	Amino alcohol derivatives
WO2002018395A1 (en) *	2000-08-31	2002-03-07	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
IL157773A0 (en)	2001-03-26	2004-03-28	Novartis Ag	2-amino-propanol derivatives
US7521192B2 (en)	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (en)	2001-04-20	2002-10-31	Sankyo Co Ltd	Benzothiophene derivative
US20040235794A1 (en)	2001-09-04	2004-11-25	Shinji Nakade	Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029184A1 (en)	2001-09-27	2003-04-10	Kyorin Pharmaceutical Co., Ltd.	Diaryl ether derivative, addition salt thereof, and immunosuppressant
CN1329372C (en)	2001-09-27	2007-08-01	杏林制药株式会社	Diaryl sulfide derivatives and their addition salts and immunosuppressants
WO2003062252A1 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Edg receptor agonists
WO2003062248A2 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
CA2473740A1 (en)	2002-01-18	2003-07-31	David Solow-Cordero	Methods of treating conditions associated with an edg receptor
CA2472680A1 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Selective s1p1/edg1 receptor agonists
PT1772145E (en) *	2004-07-16	2011-05-27	Kyorin Seiyaku Kk	Method of effectively using medicine and method concerning prevention of side effect

2004
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/en not_active IP Right Cessation
- 2004-04-06 PL PL04725895T patent/PL1613288T3/en unknown
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/en unknown
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/en active IP Right Grant
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/en not_active Expired - Lifetime
- 2004-04-06 SI SI200432283T patent/SI2316431T1/en unknown
- 2004-04-06 PT PT04725895T patent/PT1613288E/en unknown
- 2004-04-06 AR ARP040101162A patent/AR043987A1/en not_active Application Discontinuation
- 2004-04-06 GR GR20040100121A patent/GR1005052B/en unknown
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 NZ NZ542622A patent/NZ542622A/en not_active IP Right Cessation
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/en not_active IP Right Cessation
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/en not_active Application Discontinuation
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/en active IP Right Grant
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/en active Pending
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/en not_active Application Discontinuation
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 AT AT04725895T patent/ATE414508T1/en active
- 2004-04-06 NZ NZ592339A patent/NZ592339A/en not_active IP Right Cessation
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/en not_active Application Discontinuation
- 2004-04-06 FR FR0450692A patent/FR2854073B1/en not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/en unknown
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/en not_active IP Right Cessation
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/en not_active Ceased
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/en not_active Expired - Lifetime
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/en not_active Application Discontinuation
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/en not_active Expired - Lifetime
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/en not_active Ceased
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/en active IP Right Grant
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/en not_active Expired - Lifetime
- 2004-04-06 DK DK04725895T patent/DK1613288T3/en active
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 ES ES04725895T patent/ES2320767T3/en not_active Expired - Lifetime
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/en unknown
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/en not_active Expired - Lifetime
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en not_active Ceased
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/en not_active Expired - Lifetime
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/en not_active Expired - Lifetime
- 2004-04-06 ES ES200400852A patent/ES2228282B1/en not_active Expired - Fee Related
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/en not_active Ceased
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/en not_active IP Right Cessation
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/en not_active Application Discontinuation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/en unknown
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/en active
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/en not_active IP Right Cessation
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/en unknown
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/en unknown
- 2005-11-01 IS IS8114A patent/IS2682B/en unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/en active Protection Beyond IP Right Term
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/en not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/en not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/en unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/en unknown
- 2010-02-25 IS IS8885A patent/IS8885A/en unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/en not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/en not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/en not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/en active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/en active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/en unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/en unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/en unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/en unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/en active Active
- 2011-09-08 CY CY2011013C patent/CY2011013I2/en unknown
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/en not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/en active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/en unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/en unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20100600A2 (en)	2011-03-31
PT1613288E (en)	2009-02-25
PE20090743A1 (en)	2009-07-17
EP2316431B1 (en)	2015-09-30
EP2769713A1 (en)	2014-08-27
FR2854073B1 (en)	2008-03-14
CA2521325A1 (en)	2004-10-21
KR101367574B1 (en)	2014-02-25
ATE414508T1 (en)	2008-12-15
US8324283B2 (en)	2012-12-04
LU91867I9 (en)	2019-01-03
IS8885A (en)	2010-02-25
NZ586280A (en)	2011-12-22
US20190175527A1 (en)	2019-06-13
NO335120B1 (en)	2014-09-22
GR20040100121A (en)	2004-12-17
CY1110260T1 (en)	2014-04-09
CN1767819B (en)	2010-07-28
RU2012148593A (en)	2014-05-20
NZ592339A (en)	2012-09-28
EP2316431A1 (en)	2011-05-04
HK1071685A1 (en)	2005-07-29
EP1613288B1 (en)	2008-11-19
JP2004307506A (en)	2004-11-04
NO20131287L (en)	2006-01-09
ES2556947T3 (en)	2016-01-21
HRP20100601A2 (en)	2011-03-31
ES2228282B1 (en)	2006-02-16
CY1117071T1 (en)	2017-04-05
CN101797241B (en)	2013-03-27
JP5495467B2 (en)	2014-05-21
NO20055231D0 (en)	2005-11-07
DE102004016947A1 (en)	2004-10-21
US20170290787A1 (en)	2017-10-12
ES2320767T3 (en)	2009-05-28
IL197578A0 (en)	2011-07-31
HK1155647A1 (en)	2012-05-25
JP5543298B2 (en)	2014-07-09
KR20050121712A (en)	2005-12-27
SI2316431T1 (en)	2016-04-29
EP2319502A1 (en)	2011-05-11
RU2009105403A (en)	2010-08-27
EP2008650A3 (en)	2011-04-27
US20220031609A1 (en)	2022-02-03
SI1613288T1 (en)	2009-04-30
AT504853A2 (en)	2008-08-15
ES2228282A1 (en)	2005-04-01
US20130108675A1 (en)	2013-05-02
HUS1100016I1 (en)	2016-08-29
NO334116B1 (en)	2013-12-16
PE20131352A1 (en)	2013-11-14
IS8114A (en)	2005-11-01
CN1767819A (en)	2006-05-03
BRPI0409250B8 (en)	2022-01-18
GB0407819D0 (en)	2004-05-12
IL197578A (en)	2015-10-29
CN101797241A (en)	2010-08-11
RU2475236C2 (en)	2013-02-20
US20060275357A1 (en)	2006-12-07
PE20130200A1 (en)	2013-03-09
CA2707750A1 (en)	2004-10-21
FR11C0036I2 (en)	2023-12-29
ECSP056090A (en)	2006-03-01
RU2005134173A (en)	2006-09-10
KR20110005320A (en)	2011-01-17
NO20055231L (en)	2006-01-09
PL2316431T3 (en)	2016-09-30
EP2008650A2 (en)	2008-12-31
HRP20050886B1 (en)	2011-01-31
US20140011885A1 (en)	2014-01-09
LU91867I2 (en)	2011-11-08
IL170888A (en)	2010-06-16
AR043987A1 (en)	2005-08-17
SG175449A1 (en)	2011-11-28
BE2011C030I2 (en)	2023-03-07
AT501681B1 (en)	2012-04-15
RU2475237C2 (en)	2013-02-20
ITMI20040682A1 (en)	2004-07-06
JP2013177404A (en)	2013-09-09
TNSN05256A1 (en)	2007-07-10
DE602004017847D1 (en)	2009-01-02
CY2011013I1 (en)	2014-04-09
RU2010147000A (en)	2012-08-10
DK1613288T3 (en)	2009-03-23
IL242037A0 (en)	2015-11-30
AT501681A1 (en)	2006-10-15
MA27729A1 (en)	2006-01-02
GB2400318B (en)	2005-08-10
HUE028247T2 (en)	2016-12-28
PE20050396A1 (en)	2005-07-05
CA2521325C (en)	2010-09-14
DE202004021680U1 (en)	2010-04-22
NO2011016I1 (en)	2011-09-19
NO329332B1 (en)	2010-09-27
ZA200507394B (en)	2007-03-28
BRPI0409250A (en)	2006-03-28
MXPA05010860A (en)	2006-05-25
US20200237690A1 (en)	2020-07-30
RU2358716C2 (en)	2009-06-20
US20080311188A1 (en)	2008-12-18
MY141249A (en)	2010-03-31
DE122011100047I1 (en)	2011-12-15
NO20100250L (en)	2006-01-09
US20110105620A1 (en)	2011-05-05
WO2004089341A1 (en)	2004-10-21
HRP20100601B1 (en)	2016-12-02
PL1613288T3 (en)	2009-07-31
IS2682B (en)	2010-10-15
US20140255497A1 (en)	2014-09-11
DK2316431T3 (en)	2016-01-11
NO2011016I2 (en)	2012-08-27
KR20120101148A (en)	2012-09-12
TW200503784A (en)	2005-02-01
PE20150676A1 (en)	2015-05-17
AR078782A2 (en)	2011-11-30
IE20040246A1 (en)	2004-12-15
NZ542622A (en)	2009-01-31
HK1091114A1 (en)	2007-01-12
EP1613288A1 (en)	2006-01-11
GR1005052B (en)	2005-11-30
AU2004228929B2 (en)	2008-02-07
FR2854073A1 (en)	2004-10-29
CY2011013I2 (en)	2014-04-09
TWI332847B (en)	2010-11-11
US20090203798A1 (en)	2009-08-13
RU2010146697A (en)	2012-05-27
AU2004228929A1 (en)	2004-10-21
BRPI0409250B1 (en)	2017-07-11
CL2004000745A1 (en)	2005-02-11
GB2400318A (en)	2004-10-13
BE1015972A5 (en)	2005-12-06
CL2011000450A1 (en)	2011-11-25
AR078781A2 (en)	2011-11-30
JP2011006461A (en)	2011-01-13
HRP20050886A2 (en)	2006-11-30

Publication	Publication Date	Title
FR11C0036I2 (en)	2023-12-29	SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL
EE200300284A (en)	2003-10-15	Pharmaceutical compositions of NMDA receptor agonist
ZA200801575B (en)	2008-12-31	Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
ATE354362T1 (en)	2007-03-15	STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING AN AMORPHIC ACTIVE INGREDIENT
EP1648474A4 (en)	2009-03-25	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR SCALING LESIONS
EP1900368A4 (en)	2009-08-12	TABLET CONTAINING AN ACTIVE SOLUBLE INGREDIENT
MA28527B1 (en)	2007-04-03	ORAL FORMULATIONS CONTAINING LICARBAZEPINE
EA200601015A1 (en)	2006-10-27	ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION
DE112004002737D2 (en)	2006-11-23	Solvent for biogenic active pharmaceutical ingredients
EP1626961A4 (en)	2008-07-16	NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
TH72202B (en)	2019-10-25	Solid pharmaceutical constituents include S1P receptor agonist and sugar alcohol.
TH70717A (en)	2005-09-29	Solid pharmaceutical constituents include S1P receptor agonist and sugar alcohol.
TH2523A3 (en)	2006-04-24	Mouthwash products to reduce appetite
ITMI20041849A1 (en)	2004-12-29	PHARMACEUTICAL FORMULATIONS FOR THE FOOD INTEGRATION OF ANOREXIC SUBJECTS
TH75914A (en)	2006-02-23	Tetrodotoxin solid oral tolerance formulation
DK200300002U1 (en)	2003-01-03	Pharmaceutical formulations containing fluoxetine
DK200300003U1 (en)	2003-01-03	Pharmaceutical formulations containing fluoxetine
HK1071685B (en)	2006-08-04	Pharmaceutical composition comprising an s1p receptor agonist